People living with sickle cell are apprehensive about a revolutionary new one-off treatment that has just been approved for use on the NHS. | ITV News Granada ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

Editas Medicine has decided to end the development of its gene-editing therapy for thalassaemia and sickle cell disease (SCD), narrowing its R&D focus and making sweeping cuts to its workforce.